Terapet

Health Tech & Medtech · Satigny, Switzerland · Founded 2019

Next-generation imaging solutions for nuclear medicine, including proton therapy and precision medicine MoreLess

Terapet SA, a Geneva-based spin-off from CERN, specializes in advanced nuclear imaging technologies aimed at enhancing the precision and safety for cancer treatment. Their flagship product, Qualγscan, is a real-time, non-invasive quality assurance device for proton therapy, currently in the commercialization phase. Additionally, they are developing Nuclyscan, a next-generation total-body PET scanner designed for theranostic applications, with plans for deployment in 2026.

Valuation $0–100M

Headcount <100

Total funding $10–50M

Unlock exact values

Talent graph

Terapet's talent

Book a demo to see the people

Team profiled 8 named & role-tagged

Founders /100 quality score

Key operators 4 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on Terapet's cap table

Sourced from Dealroom's funding and investor records.

Seed 4 investors entered at this stage

Nina Capital

EFI

FONGIT

Innosuisse

Global footprint

Where Terapet has talent and traffic

Workforce by country

3 countries with
team presence

🇨🇭 Switzerland86.7%

🇮🇹 Italy6.7%

🇫🇷 France6.7%

3 countries shown

Market sentiment

What the market is saying about Terapet

An AI-synthesized read of the highest-engagement posts about Terapet on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Terapet on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles